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Structural basis for DNA damage-induced
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Phosphorylation of MDM2 by ATM upon DNA damage is an important mechanism for
deregulating MDM2, thereby leading to p53 activation. ATM phosphorylates multiple resi-
dues near the RING domain of MDM2, but the underlying molecular basis for deregulation
remains elusive. Here we show that Ser429 phosphorylation selectively enhances the ubi-
quitin ligase activity of MDM2 homodimer but not MDM2-MDMX heterodimer. A crystal
structure of phospho-Ser429 (pS429)-MDM2 bound to E2–ubiquitin reveals a unique 310-
helical feature present in MDM2 homodimer that allows pS429 to stabilize the closed
E2–ubiquitin conformation and thereby enhancing ubiquitin transfer. In cells Ser429 phos-
phorylation increases MDM2 autoubiquitination and degradation upon DNA damage,
whereas S429A substitution protects MDM2 from auto-degradation. Our results demon-
strate that Ser429 phosphorylation serves as a switch to boost the activity of MDM2
homodimer and promote its self-destruction to enable rapid p53 stabilization and resolve a
long-standing controversy surrounding MDM2 auto-degradation in response to DNA
damage.
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Often referred to as the guardian of the genome, p53 is animportant tumor suppressor protein in human cells1.Upon activation by cellular stress, p53 binds DNA and
activates transcription of target genes that initiate cell cycle arrest
or apoptosis to repair or destroy the stressed cells, respectively.
Consequently, mutations that reduce the ability of p53 to bind
DNA are highly oncogenic. In fact, more than half of human
tumor cells carry a TP53 mutation, and most of these are directly
connected to a reduced ability of p53 to recognize DNA2. Basal
levels of p53 are maintained under normal conditions and rapidly
elevated upon various cellular stresses. When cellular homeostasis
is attained, p53 levels are attenuated through the ubiquitin (Ub)-
proteasome system3. Thus, precise regulation of p53 activity is a
key requirement for healthy cell growth.
There is a large and not yet fully understood network of pro-
teins that are associated with p53 regulation. The most prominent
regulator of p53 is the Ub ligase (E3) MDM2, which binds to the
transactivation domain of p53 through its N-terminal p53-
binding domain, thereby inhibiting p53’s transcriptional activ-
ity4–7. Furthermore, MDM2 catalyzes ubiquitination of p53,
where monoubiquitination promotes nuclear export of p53 and
polyubiquitination leads to proteasomal degradation8–11. The C-
terminal RING domain of MDM2 is essential for ubiquitination
and requires dimerization with either itself12 or its catalytically
inactive homolog MDMX13 to form an active homodimer or
heterodimer, respectively. The importance of the homodimer and
heterodimer in E3 activity and p53 regulation are underscored by
mouse studies in which deletion of either Mdm2 or MdmX or
knock-in of a catalytically inactive Mdm2 mutant results in early
embryonic lethality due to uncontrolled p53 activity that is res-
cued upon concomitant deletion of Trp5314–19. A delay in the
embryonic lethality in MdmX-knockout mice indicates that the
heterodimer plays a role at a different stage of development that
cannot be fulfilled by the homodimer.
Under unstressed conditions, basal MDM2 levels ensure that
p53 levels are kept low20–22. However, in the presence of cellular
stress, p53’s anti-tumorigenic function needs to be activated
quickly. One key aspect of this activation process is the uncoupling
of p53 from MDM2-mediated regulation via post-translational
modifications. Upon DNA damage, p53 is phosphorylated within
its transactivation domain, thereby reducing its binding affinity for
MDM223,24; however, this is not sufficient to fully block MDM2
activity toward p5325–28, suggesting that additional regulatory
mechanisms exist. Phosphorylation of MDMX upon DNA
damage also contributes to p53 stabilization: phosphorylation of
MDMX by c-Abl impairs p53 binding29, and phosphorylation by
Chk2 and ATM kinases promotes binding of MDMX to MDM2
and subsequent ubiquitination and degradation by MDM230–32.
MDM2 also becomes phosphorylated upon DNA damage. Phos-
phorylation of MDM2’s Y394 by c-Abl impairs the inhibitory
effect of MDM2 on p5333, and phosphorylation by CK1 near
the acidic domain facilitates ubiquitination of MDM2 by the
SCFβ-TRCP complex and its subsequent degradation34.
ATM-mediated phosphorylation of MDM2 has been shown to
precede p53 stabilization after DNA damage35. ATM phosphor-
ylates MDM2 on six residues (S386, S395, S407, T419, S425, and
S429) that are close to the C-terminal RING domain and far from
the domains associated with p53 binding36. Expression of MDM2
having phosphomimetics in place of all six residues impedes
oligomerization, resulting in reduced p53 ubiquitination; this
effect is also observed in native MDM2 upon ATM
activation36,37. Moreover, phosphorylated MDM2 has a reduced
half-life that may be a result of enhanced autoubiquitination38 or
increased susceptibility to ubiquitination by SCFFBXO31 com-
plex39, thus leading to its degradation and p53 stabilization.
MDM2 auto-degradation remains controversial as this phenotype
was attributed to a loss of epitope recognition by MDM2 anti-
bodies after phosphorylation40. Studies on MDM2’s S395 showed
that phosphorylation or aspartic acid substitution leads to
p53 stabilization, whereas alanine substitution stabilizes MDM2
and causes defects in DNA damage-induced p53 stabilization41–
43, highlighting the importance of S395 phosphorylation in
MDM2 destabilization. While these cellular correlations are
informative and intriguing, it remains unclear how phosphor-
ylation promotes MDM2 degradation and whether, with six
phosphorylation sites present, multiple mechanisms may come
into play.
We have previously elucidated the crystal structure of the
MDM2-MDMX RING heterodimer bound to E2 covalently linked
to Ub (E2–Ub; the conjugated Ub is referred to as donor Ub)44. In
this complex, MDM2’s S429 is in close proximity to the donor Ub,
suggesting that phosphorylation at this residue might affect
E2–Ub recruitment. Here, we show that S429 phosphorylation
selectively enhances MDM2 homodimer E3 activity, but has no
effect on MDM2-MDMX heterodimer E3 activity. To understand
the molecular basis for this selectivity, we determine the crystal
structures of native and pS429-MDM2 RING homodimer in
complex with E2–Ub. Comparison of the structures together with
biochemical analyses reveals the basis for how pS429 stabilizes
E2–Ub to enhance E3 activity. We show that pS429-mediated
enhanced activity promotes MDM2-catalyzed autoubiquitination
in cells after DNA damage, thus resulting in its rapid degradation.
These results provide insights into phosphoregulation of MDM2.
Results
Ser429 phosphorylation boosts the activity of MDM2 homo-
dimer. ATM phosphorylates MDM2 at a region near the C-
terminal RING domain. Given the proximity of phosphorylation
sites and the RING domain, we asked whether aspartic acid
substitutions of these residues influence E2–Ub binding. We
generated an MDM2 RING domain construct (350–C) containing
six aspartic acid substitutions (S386D, S395D, S407D, T419D,
S425D, S429D; MDM2-6D) and measured its binding affinity for
UbcH5B–Ub by using surface plasmon resonance (SPR) analyses.
Like in our previous study, UbcH5B–Ub was generated by
mutating UbcH5B’s S22 to arginine and the catalytic C85 to
lysine to eliminate the contribution of backside Ub binding and to
form a stable isopeptide bond with Ub’s C terminus to mimic the
thioester linkage, respectively45. We found that MDM2-6D
exhibited an ~2.3-fold enhancement in binding affinity for
UbcH5B–Ub compared to wild-type MDM2 (hereafter MDM2-
WT indicates wild-type (WT) version of different MDM2 frag-
ments) (Table 1; Supplementary Fig. 1). Single aspartic acid
substituted variants showed that S429D substitution was the main
contributor to the binding enhancement (Table 1). A shorter
MDM2 fragment containing residues 419–C displayed a similar
affinity for UbcH5B–Ub as MDM2-350–C (Table 1), indicating
that residues 350–418 are not involved in UbcH5B–Ub binding.
Consistent with this, introduction of an S429D or S429E sub-
stitution in the MDM2-419–C fragment also improved the affi-
nity for UbcH5B–Ub by ~2-fold compared to MDM2-WT
(Table 1), suggesting that a negative charge at S429 was respon-
sible for the binding enhancement.
To verify that phosphorylated S429 also improves UbcH5B–Ub
binding, we utilized the translational insertion of O-phosphoserine
system46 to generate MDM2-419–C-pS429. Phosphorylation was
validated by Western blot using a customized antibody specific for
MDM2-pS429 (Supplementary Fig. 2a). Mass spectrometry
analysis confirmed the presence of pS429, but unphosphorylated
peptide was also detected (Supplementary Fig. 2b). Nonetheless,
MDM2-pS429 exhibited an ~2.7-fold enhancement in binding
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affinity for UbcH5B–Ub compared to MDM2-WT. This binding
enhancement is similar to that observed for the S429D and S429E
phosphomimetic mutants. We reasoned that the true binding
enhancement upon phosphorylation might be more dramatic as
our sample contained unphosphorylated MDM2. Strikingly,
when S429E substitution was introduced into the MDM2-
MDMX RING domain heterodimer, it had minimal effect on
the binding affinity for UbcH5B–Ub compared to wild-type
MDM2-MDMX (Table 1).
To assess whether the enhanced UbcH5B–Ub binding affinity
improves E3 activity, we performed in vitro autoubiquitination
assays using glutathione S-transferase (GST)-tagged MDM2-
419–C or cleaved MDM2-419–C. MDM2-S429E displayed an
increased autoubiquitination activity compared to MDM2-WT
(Fig. 1a, b and Supplementary Fig. 3a–d). In contrast, replacing
MDM2-S429E in the MDM2-MDMX heterodimer had no effect
on activity, consistent with our binding analyses (Fig. 1c, d and
Supplementary Fig. 3e). By following the autoubiquitination
reaction of the MDM2 homodimer over time, we found that the
S429E substitution improved the rate by ~1.6-fold as compared to
WT (Fig. 1e, f and Supplementary Fig. 3f). Moreover, under our
reaction conditions the ubiquitination patterns appeared to be
similar — the ubiquitinated products of the MDM2-WT reaction
after 120 s were comparable to the ubiquitinated products of the
MDM2-S429E reaction after 60–80 s (Fig. 1e). Thus, the
phosphomimetic substitution of S429 affects the rate of catalysis,
but not the nature of the ubiquitination pattern.
Structure of MDM2 RING domain homodimer bound to
UbcH5B–Ub. The effect of the MDM2 S429E substitution on
Table 1 Dissociation constants Kd of MDM2 homodimer and
MDM2-MDMX heterodimer variants for UbcH5B–Ub.
Ligand Kd (μM)
MDM2-350–C 15.7 ± 0.6
MDM2-350–C-6D 6.7 ± 0.2
MDM2-350–C-S386D 13.7 ± 0.3
MDM2-350–C-S395D 13.7 ± 0.3
MDM2-350–C-S407D 13.7 ± 0.3
MDM2-350–C-T419D 13.0 ± 0.5
MDM2-350–C-S425D 13.4 ± 0.7
MDM2-350–C-S429D 7.8 ± 0.3
MDM2-419–C 14.0 ± 0.3
MDM2-419–C-S429D 7.1 ± 0.7
MDM2-419–C-S429E 6.4 ± 0.4
MDM2-419–C-pS429 5.1 ± 0.4
cat MDM2-422–C 16.8 ± 0.3
cat MDM2-422–C-S429E 6.8 ± 0.4
MDM2-350–C/MDMX-428–C 36.7 ± 2.1
MDM2-350–C-6D/MDMX-428–C 29.2 ± 0.6
MDM2-419–C/MDMX-418–C 23.4 ± 0.8
MDM2-419–C-S429E/MDMX-418–C 17.8 ± 1.4
Standard error of mean values are indicated. Number of replicates, representative sensorgrams,
and binding curves are shown in Supplementary Fig. 1.
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Fig. 1 Phosphomimetic substitution at S429 enhances the E3 activity of the MDM2 homodimer. a Reduced SDS-PAGE showing autoubiquitination
reactions catalyzed by GST-MDM2-419–C and its S429E substitution using fluorescently labeled Ub and visualized with an Odyssey CLx Imaging System.
b Plot of relative ubiquitination activity corresponding to a. c Reduced SDS-PAGE showing autoubiquitination reactions catalyzed by GST-MDM2-419–C-
His-MDMX-418–C and its MDM2-S429E substitution using fluorescently labeled Ub and visualized with an Odyssey CLx Imaging System. d Plot of relative
ubiquitination activity corresponding to c. For b, d, data are presented as mean value ± SD from three independent experiments (n= 3). e Reduced SDS-
PAGE showing autoubiquitination reactions catalyzed by GST-MDM2-419–C and its S429E substitution over the indicated times using fluorescently
labeled Ub and visualized with an Odyssey CLx Imaging System. f A plot showing the rates of ubiquitination catalyzed by the forms of MDM2 assessed in
e. The line represents the regression line from three independent experiments (n= 3). Asterisks in a, c, and e indicate non-reducible E1–Ub product.
Uncropped gel images and InstantBlue-stained gels are shown in Supplementary Fig. 3.
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UbcH5B–Ub binding suggests that the MDM2 RING domain
homodimer and the MDM2-MDMX RING domain heterodimer
use distinguishable mechanisms to recruit UbcH5B–Ub. We have
recently determined the structure of the MDM2-MDMX RING
domain heterodimer bound to UbcH5B–Ub and proposed a
model for how the MDM2 homodimer recruits E2–Ub44. How-
ever, this model does not explain how pS429 exclusively affects
MDM2 homodimer. To better understand the E2–Ub recruit-
ment mechanism of the homodimer, we determined the structure
of the human MDM2 RING homodimer (419–C; referred to as
MDM2R and hereafter superscript R indicates the RING domain)
in complex with UbcH5B–Ub to 1.41 Å (Fig. 2a, b and Table 2).
The asymmetric unit contains two molecules of MDM2R that
form a dimer, where each MDM2R binds a UbcH5B–Ub molecule
in a similar manner (root mean square (r.m.s.) deviation of 0.16 Å
for Cα atoms between the two monomeric portions of MDM2R-
UbcH5B–Ub complex). This is in contrast to the MDM2-MDMX
heterodimer, which only binds one molecule of UbcH5B–Ub
(Fig. 2c)44.
MDM2R binds UbcH5B and Ub and arranges UbcH5B–Ub
into a closed conformation similar to that observed in the
MDM2-MDMX-UbcH5B–Ub structure44 (r.m.s. deviation of
0.33 Å for Cα atoms of the MDM2R-UbcH5B–Ub complex)
and other RING E3-E2–Ub complexes47,48. This conformation is
primarily stabilized by MDM2R-UbcH5B, MDM2R-Ub, and Ub-
UbcH5B interactions (Fig. 3a, b) that are common to both
MDM2 homodimer and MDM2-MDMX heterodimer. We have
previously highlighted the importance of these interactions by
showing that disruption of these interactions reduced the E3
activity of both the MDM2 homodimer and the MDM2-MDMX
heterodimer44. Additionally, the dimeric arrangement enables the
C-terminal tail from the second RING domain protomer to
stabilize Ub in the closed conformation in trans (Fig. 2a, b). In the
MDM2 homodimer, the last three residues of MDM2 (Y489,
F490, and P491) from the second MDM2R protomer are buried
within the MDM2R-Ub interface and pack against the
Gly35 surface of Ub in trans (Fig. 3c), whereas in the MDM2-
MDMX heterodimer, this is fulfilled by the last three residues of
MDMX (F488, I489, and A490)44. This tail–Ub interaction is
observed in other dimeric RING E3-E2–Ub complexes47,48, thus
explaining the importance of dimerization. Consistent with our
structure, alterations in MDM2’s C-terminal tail sequence were
previously shown to hinder the activity of the homodimer44,49–51.
A major structural difference between the dimers lies in
MDM2’s residues 430–436, which precede the RING domain
(Fig. 3d, e). These residues are not involved in crystal packing
contacts (Supplementary Fig. 4a) and are cradled by the N-
terminal region and C-terminal tail of the second MDM2R
protomer such that residues 432–436 adopt 310-helices in each
MDM2R protomer. The helices stabilize each other via hydro-
phobic interactions involving A434 and I435 (Figs. 2b and 3d).
L430 and P431 adopt an extended configuration and are
stabilized by hydrophobic interactions involving I435, P437,
P445, and F490 from the second MDM2R protomer (Fig. 3d). In
the MDM2-MDMX-UbcH5B–Ub complex structure, MDM2’s
residues 428–436 form a continuous α-helical structure, whereas
MDMX’s residues 428–436 adopt a 310-helical structure (Fig. 3e).
While the crystal packing contacts could contribute to the
structural configurations observed in the heterodimer (Supple-
mentary Fig. 4b,c), it seems likely that the structural differences
between the homodimer and the heterodimer are caused by
sequence differences of MDM2R and MDMX within the N-
terminal region (residues 430–436) and the C-terminal tail, which
pack against the N-terminal region in trans (Figs. 2 and 3d, e).
Consequently, the residues preceding E436 of MDM2R in the
homodimer are shifted in comparison to the heterodimer, leaving
UbcH5B
UbcH5B
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C-terminal tail of MDM2R
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C-terminal tail of MDM2R
Ub
Ub
UbcH5B
MDM2R MDMXR
Ub
UbcH5B–Ub linkage
N terminus of MDM2R
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Fig. 2 Crystal structure of human MDM2 RING domain homodimer bound to UbcH5B–Ub. a Cartoon representation of the complex. One MDM2R is
colored green and the other is in magenta. UbcH5B is in cyan and Ub is in yellow. UbcH5B–Ub linkage is indicated. Top and bottom panels are related by
90° rotation about the x-axis. b Surface representation of the complex, colored and oriented as in a (top panel). The N-terminal region preceding the RING
domain and the C-terminal tail of MDM2 are indicated. c A cartoon representation of the structure of MDM2-MDMX RING domain heterodimer bound to
UbcH5B–Ub (PDB ID: 5MNJ) oriented in the same view as in a (bottom panel). MDM2R, UbcH5B, and Ub are colored as in a and MDMX RING domain
(MDMXR) is in orange.
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them in different local environments to initiate distinct
UbcH5B–Ub contacts. In the homodimer, N433 forms hydrogen
bonds with the backbone carbonyl atom of F490 and the C-
terminal carboxylate of P491 in the second MDM2R protomer,
and these residues in turn form hydrogen bonds with the K11 and
T9 sidechains of Ub, respectively, to stabilize the closed Ub
conformation (Fig. 3d). In contrast, the continuous α-helical
structure of MDM2 in the heterodimer forms a complementary
contact with Ub’s K11 surface (Fig. 3e).
To assess the importance of the N-terminal region of MDM2R
in the context of the homodimer, we introduced arginine
substitutions to disrupt the 310-helical Ub-binding feature and
performed autoubiquitination reactions to assess their effects.
MDM2 L430R, N433R, A434R, I435R, and E436R variants had
reduced activities as compared to WT (Fig. 3f, g; Supplementary
Fig. 5a), suggesting that the observed structural features are
important for stabilization of E2–Ub in the closed conformation.
In our structure, there is no electron density for residues 419–429,
indicating that this region is disordered. However, the differences
in the structural features of residues 430–436 could account for
the effect of S429 phosphorylation in the homodimer compared
to the heterodimer.
Phosphorylated Ser429 contacts the donor Ub. To understand
the molecular basis of S429 phosphorylation on MDM2 activity,
we purified human MDM2R-pS429 with the aim to crystallize it
in complex with UbcH5B–Ub. Due to the low protein yield of the
O-phosphoserine system, we were only able to screen around the
crystallization condition of human MDM2R-UbcH5B–Ub
complex and did not obtain crystals. The sequence of MDM2
RING domain (437–C) and S429 are well conserved among
mammalian species (Supplementary Fig. 6). For example, the
RING domains of human and Felis catus (cat) MDM2 are
identical, whereas the adjacent N-terminal region differs by only
four residues (Fig. 4a). To assess whether cat MDM2 is also
regulated by S429 phosphorylation, we generated cat MDM2-
422–C-S429E and performed autoubiquitination assays and
UbcH5B–Ub binding analyses. We showed that the S429E sub-
stitution enhanced the activity (Fig. 4b, c and Supplementary
Fig. 5b) and UbcH5B–Ub binding affinity (Table 1) compared to
WT, suggesting that the pS429-mediated activity enhancement is
conserved. We then purified cat MDM2-422–C-pS429 using the
translational insertion of O-phosphoserine system46, confirmed
the phosphorylation status by Western blot (Supplementary
Fig. 2a), and assembled the complex with UbcH5B–Ub.
Diffracting crystals were obtained from crystallization condi-
tions similar to those employed for the human MDM2R-
UbcH5B–Ub complex and used to determine the structure to
1.83 Å (Fig. 4d and Table 2). The asymmetric unit contains one
MDM2 homodimer bound to two UbcH5B–Ub molecules
arranged in configuration similar to the one in the structure of
the human MDM2-UbcH5B–Ub complex (r.m.s. deviation of
1.06 Å for all Cα atoms). For both MDM2 protomers, electron
density is visible for residues 428–C. Because both S429 and
pS429 were evident in our protein preparation, we reasoned that
the abundance of pS429 could influence its occupancy. However,
we cannot exclude the possibility that only the phosphorylated
species of cat MDM2 crystallized in complex with UbcH5B–Ub.
Electron density was observed for all atoms of pS429 at a level of
Table 2 Data collection and refinement statistics.
Human MDM2-419–
C-UbcH5B–Ub
Cat MDM2-422–
C-pS429-UbcH5B–Ub
Cat MDM2-422–
C-S429E-UbcH5B–Ub
Cat MDM2-422–
C-S429E
Data collection
Space group P61 P1 P21 P21
Cell dimensions
a, b, c (Å) 129.7, 129.7, 70.5 54.6, 56.4, 60.7 56.5, 163.9, 70.6 29.2, 39.8, 104.4
α, β, γ (°) 90, 90, 120 66.44, 69.44, 89.1 90, 96.03, 90 90, 93.4, 90
Resolution (Å) 112–1.41 (1.43–1.41)a 29.2–1.83 (1.88–1.83) 70–2.18 (2.22–2.18) 23.53–1.21 (1.24–1.21)
Rmerge (%) 4.7 (66.4) 4.0 (26.0) 9.4 (71.1) 10.0 (84.5)
I/σI 19.2 (1.9) 10.2 (1.4) 9.4 (1.6) 5.1 (1.1)
Completeness (%) 100 (99.6) 95.8 (82.3) 98.8 (98.3) 98.3 (98.2)
Redundancy 8.9 (6.0) 1.8 (1.8) 3.4 (3.5) 3.2 (3.1)
CC (1/2) 1.0 (0.542) 0.996 (0.539) 0.994 (0.56) 0.991 (0.608)
Wilson B (Å2) 17.89 30.93 31.0 10.43
Refinement
Resolution (Å) 112–1.41 29.2–1.83 70–2.18 23.53–1.21
No. of reflections 129,794 49,057 65,509 71,796
Rwork/Rfree 0.139/0.173 0.211/0.242 0.166/0.227 0.171/0.212
No. of atoms
Protein 4,619 4,527 9,072 2,045
Ligand/ion 16 4 68 14
Water 546 180 420 243
B factors
Protein 25.83 38.54 38.43 16.31
Ligand/ion 38.31 28.80 44.73 22.49
Water 39.75 37.52 36.94 26.88
R.m.s. deviations
Bond lengths (Å) 0.005 0.004 0.007 0.005
Bond angles (°) 0.743 1.271 0.857 0.705
Ramachandran
Favored (%) 97.7 96.3 96.9 95.4
Outlier (%) 0 0 0 0
aValues within the parentheses are for highest-resolution shell.
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1.0σ in the calculated polder map (Fig. 4e). Despite amino acid
differences between human (L430 and L432) and cat (F430 and
H432) MDM2 sequences, the structural features of the N-
terminal region preceding the RING domain are conserved. Like
in human MDM2, cat MDM2 residues 432–436 adopt a 310-
helical turn and F430 and P431 are stabilized by hydrophobic
interactions involving I435, P437, P445, and F490 from the
second MDM2 protomer (Fig. 4f). Thus, neither the sequence
discrepancies nor phosphorylation of S429 introduced structural
rearrangements.
In the cat MDM2 structure, the phosphate moiety of pS429
contacts Ub by forming hydrogen bonds directly with the ε-
amino group of K33 and indirectly with the backbone amide of
T14 via a water molecule (Fig. 4f). To further validate these
interactions, we also determined the crystal structure of cat
MDM2-422–C-S429E bound to UbcH5B–Ub (Table 2 and
Supplementary Fig. 7a). In this structure, the interactions of the
sidechain of S429E in MDM2 resemble those of the pS429
phosphate moiety in the MDM2-pS429-UbcH5B–Ub complex:
the carboxylate moiety of the S429E sidechain in MDM2 forms a
hydrogen bond with the K33 sidechain of Ub and coordinates a
water molecule that forms a hydrogen bond with the backbone
amide of Ub’s T14 (Fig. 4g, h). In both structures, crystal packing
is facilitated by residues that precede the RING domain and that
are unique to cat MDM2 (Supplementary Fig. 7b,c).
To validate the S429E–Ub interaction, we mutated Ub’s K33 to
methionine to disrupt the hydrogen bond and performed pulse-
chased autoubiquitination assays in which UbcH5B was charged
with Ub-K33M and then mixed with human MDM2-WT or the
MDM2-S429E variant. Both MDM2 variants exhibited similar
activity with Ub-K33M (Fig. 4i, j and Supplementary Fig. 5c),
suggesting that the S429E-mediated enhanced activity with
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Ub-WT (Fig. 1a, b) was abolished. To further establish the
importance of the S429E-K33 charge–charge interaction, we
swapped the charges on MDM2 and Ub by introducing S429R in
MDM2 and K33E in Ub and performed pulsed-chased auto-
ubiquitination assays. In the presence of Ub-WT, the MDM2-
S429R variant exhibited reduced activity as compared to MDM2-
WT (Fig. 4k, l and Supplementary Fig. 5d), suggesting that the
Arg substitution might cause a charge repulsion with Ub’s K33. In
contrast, when Ub-K33E was used, MDM2-S429R displayed
enhanced activity compared to MDM2-WT (Fig. 4m, n and
Supplementary Fig. 5e), suggesting that the favorable charge
interaction between these residues is responsible for the observed
increased activity. Collectively, these results show that
pS429 stabilizes the donor Ub in the closed conformation to
enhance MDM2 activity.
Importance of Ser429 location in the homodimer. Our struc-
tures and biochemical data suggest that the location of pS429 or
S429E with respect to the RING domain is important for optimal
hydrogen bond formation with Ub’s K33. In all the structures of
MDM2 homodimer bound to UbcH5B–Ub presented here, the
N-terminal region preceding the MDM2 RING domain adopts
the same 310-helical turn configuration. A prior solution structure
of MDM2 RING domain homodimer determined by nuclear
magnetic resonance showed that this region is flexible and adopts
various conformations12, suggesting that the 310-helical turn
configuration observed in our structures might be a product of
UbcH5B–Ub binding. Since flexible or disordered regions usually
lack electron density in crystal structures, we also crystallized and
determined the structure of cat MDM2-422–C-S429E to 1.21 Å
(Fig. 5a and Table 2). The asymmetric unit contains two dimers.
The electron density for residues 429–C was visible and MDM2
adopts the same configuration as seen in the cat MDM2-422–C-
S429E-UbcH5B–Ub structure (r.m.s. deviation of 0.30 Å for all
Cα atoms). Despite contributing to crystallographic contacts, the
region preceding the RING domain is able to adopt the same 310-
helical turn configuration independent of E2–Ub binding.
MDM2-MDMX RING domain heterodimer structures have
previously been determined in the absence and presence of
E2–Ub. In the structure of MDM2-MDMX-UbcH5B–Ub
complex, the region preceding the RING domain of MDM2
adopts a continuous α-helical structure44 (Fig. 5b, left panel).
Superimposition of the MDM2-MDMX-UbcH5B–Ub complex
structure onto the MDM2-pS429-UbcH5B–Ub complex struc-
ture shows that S429 of MDM2 in the heterodimer is displaced
by ~10 Å (distance between the Cα atoms) as compared to
pS429 of MDM2 in the homodimer (Fig. 5c). In comparison, in
the structure of MDM2-MDMX alone (PDB ID: 2VJF)13,
residues 428–436 from MDM2 form a 310-helical turn similar
to the one formed by these residues in the homodimer (Fig. 5b,
right panel). Superimposition of the MDM2-MDMX structure
onto MDM2-pS429-UbcH5B–Ub shows that S429 of MDM2 in
the heterodimer is ~3.5 Å away (distance between the Cα atoms)
from pS429 of MDM2 in the homodimer and that its sidechain
faces away from Ub’s K33 (Fig. 5d). These structural
comparisons show that the distance and trajectory of the
S429 sidechain in the heterodimer preclude interactions with
Ub’s K33, thereby explaining why S429E substitution had no
effect on the activity of the heterodimer. Closer inspection of
homodimer and heterodimer structures reveals that variations in
MDM2 and MDMX sequences in the region preceding the
RING domain and in their C-terminal tail cause different
structural configurations of MDM2’s residues 429–431 in both
dimers (Fig. 5e) such that only S429 in the homodimer can
contact Ub upon phosphorylation.
To assess the importance of the position of pS429 in the
MDM2 homodimer, we performed various autoubiquitination
assays using the MDM2-S429E variant. First, we inserted an
alanine residue between S429 and L430 in MDM2 to displace the
position of S429E. Alanine insertion in MDM2-WT had a slight
reduction in activity, whereas insertion in MDM2-S429E
abolished S429E-mediated activity enhancement (Fig. 5f, g and
Supplementary Fig. 5f). Second, we disrupted the 310-helical turn
configuration by introducing the aforementioned A434R sub-
stitution. A434R alone reduced the activity compared to MDM2-
WT and was not enhanced by the additional incorporation of
S429E substitution (Fig. 5h, i and Supplementary Fig. 5g). Third,
we replaced MDM2’s C-terminal residues with the MDMX
sequence (F490I and P491A) to disrupt the packing surrounding
S429. The MDM2-F490I-P491A mutant had reduced activity as
compared to MDM2-WT and incorporation of S429E did not
improve the activity (Fig.5j, k and Supplementary Fig. 5h).
Collectively, these results underscore the importance of the
structural features surrounding S429 in enabling precise position-
ing of pS429 for Ub interaction in the homodimer.
Ser429 phosphorylation destabilizes MDM2 upon DNA
damage. Previously, S429D substitution in MDM2 was reported
to stabilize p53 in H1299 cells36. We wanted to investigate
whether this stabilization could be attributed to the enhanced
MDM2E3 activity that we observed in vitro. We previously
generated a U2OS cell line that lacks endogenous MDM2 and
contains a doxycycline-inducible p53 short hairpin RNA
(shRNA) (hereafter referred to as U2OSmod cells) to study the
effects of MDM2 mutations in cells44. To investigate the relative
stability of MDM2-WT and the phosphomimetics MDM2-S429D
and MDM2-S429E, we transfected U2OSmod cells with the
aforementioned GFP-MDM2 variants and followed their stability
in a cycloheximide chase experiment. Both MDM2-S429D and
MDM2-S429E were found to be less stable as compared to
MDM2-WT (Fig. 6a). Consistent with this observation, reduc-
tions in the protein levels of MDM2-S429D and MDM2-S429E
were evident in the total cell lysate as compared to MDM2-WT
(Fig. 6b). To investigate whether the reduced stability of the
MDM2 phosphomimetics correlates with enhanced auto-
ubiquitination activity, MDM2-S429E was incorporated with a
secondary site mutation I440K that blocks the RING domain
from binding E2–Ub and has previously been shown to abolish
MDM2’s E3 function without influencing its ability to dimerize44.
The MDM2-S429E-I440K variant was stabilized and did not get
ubiquitinated (Fig. 6b), indicating that the observed ubiquitinated
species were indeed products of autoubiquitination. Next, we
investigated the effect of MDM2-S429 phosphomimetics on
p53 stability by co-transfecting Myc-tagged p53 and GFP-MDM2
variants into unmodified U2OS cells. Cells expressing MDM2-
S429D and MDM2-S429E displayed a slightly higher level of p53
as compared to cells expressing MDM2-WT (Fig. 6c). Corre-
spondingly the p21 expression level was higher in cells expressing
MDM2-S429 phosphomimetics. The ligase-dead MDM2-S429E-
I440K caused p53 stabilization, but the p21 level was lower than
that observed in the cells expressing empty vector (EV), sug-
gesting that this MDM2 variant can still restrain p53 activity
consistent with our prior observation44. Together, these results
demonstrate that MDM2-S429 phosphomimetics exhibit
enhanced activity in cells, but because the increased activity
promotes its autoubiquitination and degradation, there is less
MDM2 available to facilitate substrate degradation.
Since S429 is phosphorylated after DNA damage, we also
performed cycloheximide chase experiments to compare the
relative stability of MDM2-WT and MDM2-S429A in U2OSmod
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cells in the presence and absence of DNA damage-inducing
etoposide treatment. We used GFP-tagged MDM2 and detected
with anti-GFP antibody to avoid anti-MDM2 antibody epitope-
masking effects by MDM2 phosphorylation after DNA damage40.
There was no observable difference in the relative stability of the
MDM2 variants in the absence of etoposide stress (Fig. 6d).
However, etoposide-induced DNA damage led to faster degrada-
tion of MDM2-WT, suggesting that the MDM2-S429A was
partially protected from DNA damage-induced downregulation.
Consistent with this, etoposide treatment led to an increase in
MDM2-S429 phosphorylation, confirmed by Western blot using
a customized MDM2-pS429 antibody (Fig. 6e). Trace amounts of
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MDM2-pS429 were detected in untreated cells, indicating that
S429 phosphorylation might occur at a basal level even in the
absence of DNA damage. Etoposide-treated cells also showed
enhanced MDM2-WT autoubiquitination concomitant to it being
highly phosphorylated at S429 under similar conditions (Fig. 6f).
In contrast, differences in ubiquitination of MDM2-S429A with
and without etoposide treatment were minimal (Fig. 6f).
Collectively, these results suggest that under DNA damage-
induced stress, MDM2 undergoes S429 phosphorylation, which
enhances its autoubiquitination and subsequent degradation, and
may eventually lead to p53 stabilization.
Discussion
Our present work provides a mechanism by which pS429
enhances MDM2’s E3 activity to promote its self-ubiquitination
and rapid degradation upon DNA damage. Our structure of
native MDM2-UbcH5B–Ub complex shows that the MDM2
homodimer is an active and competent E3 in the absence of
pS429. The MDM2 homodimer utilizes the RING domain and
the C-terminal tail to arrange UbcH5B–Ub into the closed cata-
lytically active conformation via a mechanism similar to the
MDM2-MDMX heterodimer and other dimeric RING E3s44,47,48.
As the activity of RING E3s is governed by their ability to
populate E2–Ub into the closed conformation52, pS429 increases
the activity by providing an additional interaction with the donor
Ub to reinforce the closed E2–Ub conformation. Thus, S429
phosphorylation does not function as an off/on switch to robustly
activate the E3 activity as observed in E3s such as CBL53 and
PARKIN54. Instead, it serves to mildly boost MDM2’s activity.
This mechanism might have evolved as a fine-tuning tool in
mammals where S429 is mostly conserved (Supplementary
Fig. 6). In other classes of animal, such as fish, this residue is not
conserved despite high sequence identity RING domain residues,
indicating that it is not essential for MDM2’s E3 function.
ATM phosphorylates six residues (S386, S395, S407, T419,
S425, and S429) adjacent to MDM2’s RING domain upon DNA
damage36. How do these phosphorylation sites regulate MDM2?
Studies on MDM2’s S395 showed that the S395D mutant
exhibited similar stability as WT under unstressed conditions and
was rapidly degraded like WT following DNA damage, whereas
the S395A mutant was protected from degradation42,43. These
findings suggest that phosphorylation of S395 together with other
phosphorylation sites destabilizes MDM2. Our present study
shows that S429 phosphorylation or phosphomimetic substitu-
tion destabilizes MDM2 by increasing its ubiquitination activity
in a manner that is dependent on MDM2’s RING domain as the
ligase-dead I440K substitution protects MDM2 from ubiquitina-
tion. These results suggest that DNA-damage-induced S429
phosphorylation enhances MDM2’s activity and accelerates
MDM2 self-ubiquitination to promote its rapid degradation. Our
data show that pS429 only exerts its effect in the context of the
MDM2 homodimer. Thus, while ATM-mediated MDM2 phos-
phorylation was reported to decrease MDM2 oligomerization36,
MDM2 must be able to dimerize for pS429 to promote its
autoubiquitination. In previous studies, it was unclear whether
MDM2 autoubiquitination caused a decrease in MDM2 protein
levels after DNA damage as they relied on MDM2 antibodies that
failed to recognize phosphorylated MDM240. We circumvented
this issue by using GFP-tagged MDM2 and detecting with anti-
GFP antibody. Moreover, our structures and biochemical analyses
provide strong evidence that DNA damage-induced S429 phos-
phorylation enhances MDM2 autoubiquitination and degrada-
tion. It is noteworthy that other E3s such as SCFFBXO31
complex39, p300/CBP-associated factor55, anaphase-promoting
complex/cyclosome56, and SCFβ-TRCP complex34 have been
reported to promote MDM2 ubiquitination and degradation after
DNA damage. While it remains unclear how multiple E3s,
including MDM2 itself, can act in a concerted manner or func-
tion specifically under certain cellular contexts, the availability of
multiple mechanisms ensures that MDM2 is rapidly eliminated to
allow p53 stabilization.
We show that pS429 only enhances the activity of the MDM2
homodimer, but does not affect the activity of the MDM2-
MDMX heterodimer. Comparison of the structures of the MDM2
homodimer and the MDM2-MDMX heterodimer bound to
UbcH5B–Ub reveals a distinct structural feature in the homo-
dimer that allows pS429 to interact with Ub. Our findings suggest
that ATM-mediated MDM2 phosphorylation has distinct effects
on the MDM2 homodimer and MDM2-MDMX heterodimer.
Prior studies showed that MDMX is degraded by MDM2 after
DNA damage57,58. This process is likely achieved by the hetero-
dimer as MDMX with a C-terminal tag, which blocks E2–Ub
binding and abolishes the heterodimer’s activity44, is resistant to
ubiquitination and degradation by MDM257. It remains unclear
whether ATM phosphorylates MDM2 in the context of the
MDM2-MDMX heterodimer after DNA damage, but a study
showed that unlike MDM2, the rate of DNA damage-induced
MDMX degradation is not appreciably affected by the MDM2
S395A mutant43, suggesting that ATM-mediated MDM2 phos-
phorylation does not regulate heterodimer stability. Future stu-
dies are required to address the complexity of phosphoregulation
of MDM2 in the context of homodimer and heterodimer.
Our study shows that MDM2 S429 phosphorylation occurs
after DNA damage and is consistent with a prior observation36.
The structures and biochemical analyses presented here demon-
strate that pS429 serves to enhance the activity of the homodimer.
Fig. 5 Importance of the structural features at the N terminus of the MDM2 RING domain homodimer. a Cartoon representation of the structure of cat
MDM2-422–C-S429E. b Cartoon representation of the MDM2-MDMX portion of MDM2-MDMX-UbcH5B–Ub complex structure (PDB ID: 5MNJ; left
panel) and MDM2-MDMX RING domain structure (PDB ID: 2VJF; right panel) shown in the same view as in a. c Comparison of the location of pS429 in
cat MDM2-422–C-pS429-UbcH5B–Ub structure and S429 in MDM2-MDMX-UbcH5B–Ub structure (PDB ID: 5MNJ). The MDM2-MDMX RING domain
from the structure of MDM2-MDMX-UbcH5B–Ub complex was superimposed onto the structure of cat MDM2-422–C-pS429-UbcH5B–Ub complex.
d Comparison of the location of pS429 in cat MDM2-422–C-pS429-UbcH5B–Ub structure and S429 in MDM2-MDMX RING domain structure (PDB ID:
2VJF). The MDM2-MDMX structure was superimposed onto the structure of cat MDM2-422–C-pS429-UbcH5B–Ub complex. e Close-up views of dimer
interaction at the N terminus of MDM2 in the structures of cat MDM2-422–C-pS429-UbcH5B–Ub complex (left panel) and MDM2-MDMX RING domain
(PDB ID: 2VJF; right panel). For a–e, all coloring is as described in Fig. 2, except MDM2R in the heterodimer is colored gray. Key residues in c–e are shown
in sticks and atoms are colored as in Fig. 4f. Distances between the Cα atoms of pS429 and S429 are indicated in the homodimer in c and in the
heterodimer in d. f, h, j Reduced SDS-PAGE showing autoubiquitination reactions catalyzed by GST-MDM2-419–C variants using fluorescently labeled Ub
and visualized with an Odyssey CLx Imaging System. Asterisks indicate non-reducible E1–Ub product. In f, Ala_ins indicates insertion of an alanine between
residues 429 and 430 in MDM2. Uncropped gel images and InstantBlue-stained gels are shown in Supplementary Fig. 5f–h. g, i, k Plots showing the
relative ubiquitination activity of MDM2 variants in f, h, j, respectively. Data are presented as mean value ± SD from three independent experiments
(n= 3).
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We anticipate that pS429 would enhance MDM2-catalyzed ubi-
quitination reactions, including autoubiquitination and substrate
ubiquitination in cells. However, enhanced autoubiquitination
destabilizes MDM2 and presumably leads to substrate stabiliza-
tion. Consistent with this notion and as observed previously36, we
showed that p53 is stabilized in the presence of MDM2-S429
phosphomimetics as compared to MDM2-WT. However, if
MDM2 engages with substrates other than p53, phosphorylation
of S429 could enhance substrate ubiquitination. MDM2 has been
shown to associate with Nbs1 of the Mre11-Rad50-Nbs1 complex
upon DNA damage to inhibit DNA repair59,60, but it remains
unclear whether its E3 activity is associated with this process.
Future studies on p53-independent functions of MDM2 after
DNA damage could reveal additional roles of S429 phosphor-
ylation. Interestingly, we observed basal S429 phosphorylation
without etoposide treatment. This suggests that it might have a
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Fig. 6 DNA damage-mediated S429 phosphorylation effects in cells. a Immunoblots showing the stability of MDM2 variants from lysates of U2OSmod
cells expressing GFP-MDM2 variants treated with cycloheximide for indicated times. The immunoblots were analyzed by anti-GFP or anti-actin antibodies
as indicated. b Immunoblots of MDM2 ubiquitination from lysates of U2OSmod cells transfected with plasmids expressing GFP-MDM2 variants or empty
vector (EV) along with His-Ub and treated with MG132. The cell lysates and Ni-NTA pull-down products were analyzed by immunoblotting with anti-GFP
or anti-actin antibodies as indicated. c Immunoblots showing the effects of MDM2 variants on p53 and p21. Unmodified U2OS cells were transfected with
plasmids expressing GFP-MDM2 variants or EV and Myc-tagged p53. Lysates were analyzed by immunoblotting using anti-GFP, anti-Myc tag, anti-p21, or
anti-actin antibodies as indicated. d Immunoblots showing the stability of MDM2 variants from lysates of U2OSmod cells expressing GFP-MDM2 variants
left untreated (top panel) or treated with etoposide (bottom panel) for 6 h, followed by cycloheximide treatment for indicated times. The immunoblots
were analyzed by anti-GFP or anti-actin antibodies as indicated. e Immunoblots showing MDM2 S429 phosphorylation in the absence and presence of
etoposide treatment. U2OSmod cells were transfected with plasmids expressing GFP-MDM2 variants or EV and treated with etoposide where indicated.
The cell lysates and GFP-Trap pull-down products were analyzed by immunoblotting with anti-GFP, anti-MDM2-pS429, or anti-actin antibodies as
indicated. Low= low exposure; high= high exposure. f Immunoblots of MDM2 ubiquitination from lysates of U2OSmod cells transfected with plasmids
expressing GFP-MDM2 variants or EV, along with His-Ub in the absence and presence of etoposide. Prior to harvesting, cells were treated with MG132.
The cell lysates and Ni-NTA pull-down products were analyzed by immunoblotting with anti-GFP or anti-actin antibodies as indicated. Actin loading control
blots were included for all panels. All the experiments were performed in triplicate with similar results. Raw data are provided in Supplementary Fig. 10.
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role under unstressed conditions and will require further
investigation.
In conclusion, our study provides structural insights into
MDM2 phosphorylation near the RING domain and reveals a
distinct role of S429 phosphorylation in stabilizing E2–Ub to
stimulate self-degradation upon DNA damage. The findings
presented here will assist in unveiling the molecular basis of
MDM2 phosphoregulation, which is an important aspect in
diagnostics and might serve as a target in drug design.
Methods
Recombinant protein preparation. All constructs were generated by standard
PCR-ligation techniques and verified by DNA-sequencing. MDM2 variants were
cloned into pGEX4T1 vector containing an N-terminal GST-tag, followed by a
tobacco etch virus (TEV) cleavage sequence. MDMX variants were cloned into
pRSFDuet-1 vector with an N-terminal 12× His-tag, followed by a TEV cleavage
site. A G443T substitution was included only in cat MDM2 variants for structure
determination to improve the solubility of MDM2 after TEV cleavage. G443T has
minimal effects on the folding of MDM2 RING domain or UbcH5B–Ub binding as
revealed by our structures (Supplementary Fig. 8). All non-phosphorylated MDM2
variants were expressed in Escherichia coli BL21(DE3) GOLD. For the MDM2-
MDMX heterodimer, BL21(DE3) GOLD cells were co-transformed with MDM2
and MDMX constructs. Cells were grown at 37 °C in Luria-Bertani medium to an
OD600 of 0.6–0.8 and induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) at 18–20 °C overnight. Cells were lysed in 50 mM Tris-HCl, pH 7.6, 0.4 M
NaCl, 1 mM dithiothreitol (DTT), and 2.5 mM phenylmethylsulfonyl fluoride
(PMSF). For SPR analyses and in vitro activity assays, GST-MDM2 variants were
purified by Glutathione Sepharose (GE Healthcare) affinity chromatography, fol-
lowed by size-exclusion chromatography to isolate dimeric MDM2 (Supplementary
Fig. 9) and GST-MDM2-His-MDMX variants were purified by Ni-NTA resin,
followed by Glutathione Sepharose affinity chromatography. For protein crystal-
lization and activity assays of cleaved MDM2 (Supplementary Fig. 9), GST-MDM2
variants were subjected to TEV cleavage and further purified by size-exclusion
chromatography using a HiLoad Superdex 75 26/60 (GE Healthcare) gel filtration
column. To generate MDM2-pS429, EcAR7 cells were co-transformed with an
MDM2 construct containing the codon for S429 replaced with a TAG codon
(Addgene 52055) and a pKD-SepRS-EFSep-5xtRNASep plasmid (Addgene 52054)46.
Cells were grown at 30 °C in Terrific Broth supplemented with 2 mM phospho-
serine to an OD600 of 2.0 and induced with 0.5 mM IPTG at 25 °C for 20 h. Cells
were lysed in 50 mM Tris-HCl, pH 7.6, 0.4 M NaCl, 0.05 M NaF, 1 mM Na3VO4,
1 mM DTT, and 2.5 mM PMSF. GST-MDM2-pS429 variants were purified as the
native MDM2 described above. All MDM2 and MDM2-MDMX variants were
buffer exchanged into 50 mM Tris-HCl, pH 7.6, 0.4 M NaCl, and 1 mM DTT. His-
tagged human UBA1 and untagged Arabidopsis thaliana Uba145 were charged with
GST-Ub with 5 mM MgCl2 and 5 mM ATP for 2 h at 4 °C and purified by
glutathione-affinity chromatography eluted with 25 mM DTT, followed by anion
exchange chromatography. Untagged UbcH5B variants were expressed from
pRSF_1b and purified by SP sepharose chromatography, followed by gel filtration
chromatography45. His-tagged Ub was purified by Ni-NTA resin45. To generate
stably conjugated UbcH5B S22R, C85K–Ub (refers to as UbcH5B–Ub)45, His-
tagged Ub, untagged UbcH5B S22R C85K, and untagged A. thaliana Uba1 were
mixed together in 50 mM Tris-HCl, pH 9.0, 0.2 M NaCl, 10 mM MgCl2, and 10
mM ATP at 30 °C for 1 day and subsequently purified by Ni-NTA affinity chro-
matography, followed by treatment with TEV protease to remove the His-tag and
further purification by cation exchange and size-exclusion chromatography using a
HiLoad Superdex 75 26/60 gel filtration column. Fluorescently labeled Ub was
expressed in pGEX4T1 vector as a GST-TEV-GGSC fusion construct. After TEV
cleavage, the protein was subjected to size-exclusion chromatography using a
HiLoad Superdex 75 26/60 gel filtration column equilibrated in phosphate-buffered
saline (PBS) buffer containing 1 mM TCEP (tris(2-carboxyethyl)phosphine),
incubated with IRDye® 800CW Maleimide (LI-COR) for 3 h at 20 °C (five-fold
excess of Ub) and desalted twice using ZebaTM Spin Desalting Columns (Thermo
Fisher). Protein concentrations were determined by absorbance at 280 nm for Ub
variants and Bio-Rad protein assay with bovine serum albumin (BSA) as a standard
for other proteins.
SPR binding analyses. SPR experiments were performed at 25 °C on a Biacore
T200 instrument using a CM-5 chip (GE Healthcare) with coupled anti-GST
antibody44. GST-tagged MDM2 variants were coupled on the chip and a serial
dilution of UbcH5B–Ub in running buffer containing 25 mM Tris-HCl, pH 7.6,
150 mM NaCl, 0.1 mgml−1 BSA, 1 mM DTT, and 0.005% (v/v) Tween-20 was
used as analyte. Two technical replicates were performed and data were analyzed
using Biacore T200 BIAevaluation (GE Healthcare) and Scrubber2 (BioLogic
Software) after background subtraction (GST alone).
Autoubiquitination assays. Autoubiquitination assays were performed at 23 °C.
UbcH5B (5 μM) was pre-charged with fluorescently-labeled Ub (50–80 μM) in the
presence of UBA1 (0.2 μM) in 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM
MgCl2, and 5 mM ATP for 15–30 min. The reaction was then initiated by the
addition of GST-MDM2 (0.8 μM) or cleaved MDM2 variants (3 μM) in PBS buffer,
stopped after 0 and 90 s or indicated time points with 4× LDS loading dye con-
taining 400 mM DTT and resolved by sodium dodecyl sulfate-polyacrylamide gel,
followed by visualization with an Odyssey CLx Imaging System (LI-COR Bios-
ciences) and staining with InstantBlue. Three independent reactions were per-
formed. Concentrations in parenthesis indicate the final concentration in the assay.
The ubiquitinated MDM2 species were quantified using the LI-COR Image Studio
Litesoftware (version 5.2.5). Background subtraction was performed using the zero
time point from each reaction and subsequently normalized to the amount of E3
loaded based on quantification of the InstantBlue-stained gel. For Figs. 1b, d and
4c, j, l, n, three independent reactions were loaded on the same gel for quantifi-
cation. For Figs. 1f, 3g, and 5g, i, k, three independent reactions were loaded on
different gels, but processed in parallel, and data were normalized across replicates
from different gels based on the zero time point from each replicate. Ubiquitination
activity relative to WT and standard deviation are presented.
Crystallization. All crystals were screened by sitting drop vapor diffusion tech-
nique and where required optimized by hanging drop vapor diffusion method by
mixing protein and reservoir solution at 1:1 ratio at 19 °C.
Cat MDM2-422–C-pS429-UbcH5B–Ub complex: Cat MDM2-422–C-pS429
(5.1 mg ml−1), and UbcH5B–Ub (14.1 mgml−1) were mixed in a 1:1 molar ratio.
Crystals were obtained in a condition containing 0.1 M Tris-HCl, pH 8.0, 15% (w/
v) PEG 2000 MME and 0.1 M KCl, and flash-frozen in 0.1 M HEPES, pH 8.0, 27%
(w/v) PEG3350, 0.2 M NaCl, and 25% (v/v) ethylene glycol.
Cat MDM2-422–C-S429E-UbcH5B–Ub complex: Cat MDM2-422–C-S429E
(14.9 mgml−1) and UbcH5B–Ub (14.5 mgml−1) were mixed in a 1:1 molar ratio.
Crystals were obtained in a condition containing 0.1 M Tris-HCl, pH 8.5, 20% (v/v)
PEG Smear High, and flash-frozen in 0.1 M Tris-HCl, pH 8.5, 20% (w/v) PEG8000,
0.2 M NH4NO3, and 25% (v/v) ethylene glycol.
Human MDM2-419–C-UbcH5B–Ub complex: Human MDM2-419–C
(7.3 mgml−1) and UbcH5B–Ub (14.5 mgml−1) were mixed in a 1:1 molar ratio.
The crystals were initially obtained in a condition containing 0.1 M BICINE, pH
9.3, and 22% (v/v) PEG Smear Broad and subsequently used as micro-seeds for
optimization. The final crystal was grown in 0.1 M SPG, pH 7.0, 10% (w/v) PEG
Smear Broad, 0.15 M NH4NO3, and flash-frozen in 0.1 M SPG, pH 7.0, 13% (w/v)
PEG Smear Broad, 0.12 M NH4NO3, and 25% (v/v) glycerol.
Cat MDM2-422–C-S429E: Crystals of Cat MDM2-422–C-S429E (14.9 mgml−1)
were obtained in a condition containing 0.1 M MMT, pH 9.0, and 25% (w/v)
PEG1500 and flash-frozen in 0.1 M Tris-HCl, pH 8.5, 20% (w/v) PEG8000, 0.2 M
NH4NO3, and 25% (v/v) ethylene glycol.
Structure determination. Data collection was carried out at beamlines I03, I04,
and I04-1 at Diamond Light Source (DLS). Datasets were processed by automated
X-ray Detector Software (XDS)61 pipeline and reduced with fast_dp package for
cat MDM2-pS429-UbcH5B–Ub complex or XIA2 package62 for all other datasets.
Initial phasing was accomplished by molecular replacement with PHASER63 using
the coordinates for UbcH5B, Ub, and MDM2 from PDB ID: 5MNJ. The atomic
models were built with COOT64 and refined in REFMAC565 and PHENIX66. The
final model for cat MDM2-422–C-pS429-UbcH5B–Ub complex was refined to
1.83 Å and contained two copies of MDM2 (chains A and D residues 428–491),
two copies of UbcH5B (chains B and E residues 2–147), and two copies of Ub
(chains C and F residues 1–76). The final model for human MDM2-419–C-
UbcH5B–Ub complex was refined to 1.41 Å and contained two copies of MDM2
(chains A and D residues 429–491), two copies of UbcH5B (chains B and E
residues 2–147), and two copies of Ub (chains C and F residues 1–76). The final
model for cat MDM2-422–C-S429E-UbcH5B–Ub complex was refined to 2.18 Å
and contained four copies of MDM2 (chain A residues 423–491, chains D and G
residues 428–491, and chain J residues 429–491), four copies of UbcH5B (chains B,
E, H, and K residues 2–147), and four copies of Ub (chains C, F, I, and L residues
1–76). The final model for cat MDM2-422–C-S429E was refined to 1.21 Å and
contained four copies of MDM2 (chain A residues 429–C, chains B and D residues
424–C, and chain C residue 427–C). Where the electron density was insufficient for
modeling side chains, alanine stubs were built instead. Statistics for the final
refinement are shown in Table 2. Polder density maps67 were calculated in PHE-
NIX to confirm the region surrounding pS429 and S429E. All figures were created
with PYMOL (Schrödinger).
Mammalian plasmids, chemicals, and antibodies. Full-length human MDM2-
WT was cloned into pGZ21dxZ-GFP, and using site-directed mutagenesis, the
following mutants were generated: MDM2-S429A, MDM2-S429D, MDM2-S429E,
MDM2-I440K, and MDM2-S429E-I440K. The following chemicals were used:
cycloheximide (Sigma-Aldrich, cat. no. C1988), MG132 (Sigma-Aldrich, cat. no.
474787) and etoposide (Sigma-Aldrich, cat. no. E1383). Cycloheximide was dis-
solved in water and used at a final concentration of 50 μg ml−1, while etoposide
and MG132 were dissolved in dimethyl sulfoxide and used at final concentrations
of 50 μM each. The cells were treated with etoposide for 6 h and with MG132 for
4 h prior to harvesting. The primary antibodies used in this study include mouse
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anti-GFP (Santa Cruz Biotechnology, cat. no. sc-81045, 1:1000 for Western blot),
customized rabbit anti-MDM2-pS429 (Eurogentec, 1:1000 for Western blot),
mouse anti-Myc tag (Cell Signaling Technology, cat. no. 2276, 1:1000 for Western
blot), rabbit anti-p21 (Cell Signaling Technology, cat. no. 2947, 1:1000 for Western
blot), and goat anti-actin (Santa Cruz Biotechnology, cat. no. sc-1616, 1:1000 for
Western blot). Anti-MDM2-pS429 antibody was generated by Eurogentec; Ac-
KEESVESpSLPLN-CONH2 peptide was used for rabbit immunization. Subse-
quently, anti-MDM2-pS429 antibody was purified by double affinity columns with
enrichment on modified peptide, followed by depletion against unmodified pep-
tide. The secondary antibodies used were goat anti-mouse IRDye 800CW (LI-COR
Biosciences, cat. no. 925-32210, 1:15000 for Western blot), goat anti-rabbit IRDye
680LT (LI-COR Biosciences, cat. no. 925-68021, 1:20,000 for Western blot), and
donkey anti-goat IRDye 800CW (LI-COR Biosciences, cat. no. 925-32214, 1:15,000
for Western blot). GFP-Trap was purchased from Chromotek.
Mammalian cell maintenance and transfections. Human osteosarcoma U2OS
cells (ATCC) with MDM2-knockout and doxycycline-inducible p53 shRNA
(U2OSmod)44 and unmodified U2OS cells were cultured in Dulbecco’s modified
Eagle’s medium, supplemented with 10% fetal bovine serum, 0.1 mg ml−1 strep-
tomycin, 100 Uml−1 penicillin, 20 mM L-glutamine, and 6 mg l−1 gentamicin
reagent solution (Invitrogen, USA). For U2OSmod cells, the medium was further
supplemented with 50 μg ml−1 doxycycline to keep p53 knocked down. The cells
were cultured in monolayer at 37 °C in 5% CO2 and transfected using jetPRIME
transfection reagent (Polyplus transfection) following the manufacturer’s protocol.
For cycloheximide chase experiments (Fig. 6a, d), U2OSmod cells were transfected
with 2.5 μg MDM2 variants. Cell-based ubiquitination assays (Fig. 6b, f) were
performed by transfecting U2OSmod cells with 5 μg MDM2 variant or EV as
indicated in the figures, along with 1 μg 12× His-Ub. In Fig. 6c, U2OS cells were co-
transfected with 1 μg Myc-p53 and 5 μg of the indicated MDM2 variant or EV,
while in Fig. 6e, U2OSmod cells were transfected with 5 μg MDM2 variant or EV as
indicated. Cells were harvested 36 h post transfection.
Cycloheximide chase assay. U2OSmod cells were transfected with constructs as
shown in Fig. 6a, d and maintained for 36 h. Cells were then treated with fresh
medium containing 50 μg ml−1 cycloheximide and harvested at time points as
indicated in Fig. 6a, d. Whole-cell lysates were prepared and the stability of MDM2
variants were checked through immunoblotting.
Preparation of lysate for analyses. Whole-cell lysates were prepared in 50 mM
Tris-HCl, pH 7.2, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) IGEPAL CA-630,
and freshly supplemented with protease inhibitor cocktail, 2.5 mM PMSF,
0.5 mM DTT, and 1 mM EDTA. For immunoprecipitation (IP), 0.5 mg of freshly
prepared lysates were incubated with 35 μL (50% slurry) GFP-Trap for 1 h at
4 °C on a rotatory shaker. The beads were then washed twice with IP lysis buffer
and once with IP wash buffer (IP lysis buffer modified to contain 200 mM NaCl
and 1 mM DTT). The beads were eluted by incubating at 95 °C for 10 min with
40 μL 2× protein loading dye. For Western blotting of whole-cell lysates, 50 μg
protein was loaded per lane. Protein samples were separated by SDS-PAGE in
NuPAGE™ 4–12% Bis-Tris gels (Thermo Fisher Scientific) using MES-SDS
running buffer and then transferred onto nitrocellulose membranes from Trans-
Blot® Turbo™ Transfer Packs (Bio-Rad) using a Trans-Blot® Turbo™ Transfer
System (Bio-Rad). The blots were incubated with the indicated primary anti-
bodies at 4 °C overnight and visualized after incubation with secondary anti-
bodies using an Odyssey CLx Imaging System. Immunoblots for Fig. 6a–d were
quantified using the LI-COR Image Studio Lite software. Band intensities from
each lane were quantified and then normalized using actin band intensities. For
Fig. 6a, d, assigned values for each band intensity are relative to the zero time
point of the corresponding condition, and for Fig. 6c, values for each band are
relative to EV.
Cell-based ubiquitination assay. Cells were transfected with plasmids expressing
His-Ub and full-length GFP-MDM2 variants as indicated. Thirty-six hours after
transfection, cells were harvested following treatment with 50 μM MG132 for 4 h.
Whole-cell lysates were prepared in IP lysis buffer (without DTT) with three 20 s
cycle of sonication at 20% amplitude. Protein concentrations were measured using
a Bradford assay and 0.5 mg total protein for each set was normalized for volume
and then mixed with Ubiquitination buffer A (UBA) buffer (6M GuHCl, 0.3 M
NaCl, 50 mM phosphate pH 8.0, 100 μg ml−1 NEM) to a final volume of 1 mL.
Dynabeads His-tag matrices (Invitrogen) were added to the lysates and incubated
on a rotatory shaker at 4 °C overnight. The next day, the beads were sequentially
washed with UBA, Ubiquitination buffer B (UBB), Ubiquitination buffer C (UBC),
and PBS (UBB=UBA and UBC 1:1; UBC= 0.3 M NaCl, 50 mM phosphate, pH
8.0, 100 μg ml−1 NEM) and eluted in 2× protein loading dye by incubating at 95 °C
for 10 min. The eluted samples were resolved by SDS-PAGE and immunoblotted
with the antibodies as indicated in Fig. 6. The ubiquitinated MDM2 variant species
were quantified using the LI-COR Image Studio Lite software and values assigned
for each band are relative to WT.
MS analysis. GST-MDM2-419–C-pS429 was reduced with 10 mM DTT and
alkylated with 55 mM iodoacetamide and finally digested with trypsin (Promega).
Digested peptides were desalted using StageTip68. Tryptic peptides were separated
by nanoscale C18 reverse-phase liquid chromatography using an EASY-nLC 1200
(Thermo Fisher Scientific) coupled online to an Orbitrap Q-Exactive HF mass
spectrometer (Thermo Fisher Scientific) via nanoelectrospray ion source (Thermo
Fisher scientific). Peptides were separated on a 50 cm fused silica emitter (New
Objective) packed in house with reverse-phase ReprosilPur Basic 1.9 µm (Dr.
Maisch GmbH). For the full scan, a resolution of 60,000 at 250 Th was used. The
top ten most intense ions in the full MS were isolated for fragmentation with a
target of 50,000 ions at a resolution of 15,000 at 250 Th. MS data were acquired and
processed using the XCalibur software (Thermo Fisher Scientific). The MS Raw
files were processed with the MaxQuant software69 (version 1.5.5.1) and searched
with Andromeda search engine70, querying UniProt and a fasta database con-
taining the MDM2 modified sequences used in the experiment. Database was
searched requiring specificity for trypsin cleavage and allowing maximum two
missed cleavages. The iodoacetamide derivative of cysteine was specified as a fixed
modification. Protein N-terminal acetylation, oxidation of methionine, and phos-
phorylation of serine, threonine, and tyrosine were all specified as variable mod-
ifications. The peptide, protein, and site false discovery rate was set in MaxQuant to
1%. Scaffold (version 4.8.4, Proteome software Inc., Portland, OR) was used to
validate MS/MS-based peptide and protein identifications and to visualize the MS/
MS spectra.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Atomic coordinates and structure factors are deposited in the Protein Data Bank with
accession codes of 6SQO (human MDM2-419–C-UbcH5B–Ub complex), 6SQS (cat
MDM2-422–C-pS429-UbcH5B–Ub complex), 6SQR (cat MDM2-422–C-S429E-
UbcH5B–Ub complex), and 6SQP (cat MDM2-422–C-S429E). Raw data for Fig. 1a, c, e
are provided in Supplementary Fig. 3, raw data for Figs. 3f, 4b, i, k, m, and 5f, h, j are
provided in Supplementary Fig. 5 and raw data for Fig. 6 are provided in Supplementary
Fig. 10. All data are available from the authors upon reasonable request.
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